The Expanding Therapeutic Landscape in IgA Nephropathy: Applying Evidence-Based Strategies and Guideline Updates for Managed Care

Program Description

IgA nephropathy (IgAN) is characterized by the deposition of immunoglobulin A (IgA) antibodies in the kidneys. This build up triggers inflammation and damage, which can manifest as progressive kidney damage requiring dialysis or kidney transplantation. Therefore, efforts that support early diagnosis and intervention to preserve kidney function have garnered attention, and research has uncovered therapies with novel mechanisms of action. This webinar will focus on the 2025 KDIGO guideline updates and clinical evidence for approved and emerging therapies for IgAN, as well as the challenges associated with current therapies and the goals of treatment. Managed care professionals will discuss considerations within the evolving treatment paradigm, including cost analyses, strategies to ensure access to novel therapies, and insights on formulary management and treatment pathways.

Target audience: Managed Care Pharmacist

Type of activity: Application
Release date: June 2, 2025
Expiration date: June 2, 2026

Time to complete activity: 1.0 hour

Learner level: Foundational
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Examine the pathophysiology and disease progression of IgA nephropathy and the clinical challenges and burden for patients.
• Explain the treatment goals, the disease-specific relevance of proteinuria, and other recommendations from the KDIGO guidelines for the treatment of IgAN.
• Analyze the clinical trial data, MOA, and cellular targets for emerging pharmacologic treatments in IgA nephropathy.
• Identify disease management protocols and care pathways that promote early diagnosis and treatment to delay or prevent disease progression in IgAN.

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hours (0.10 CEU) under the ACPE universal activity number 0290-9999-25-172-H01-P. The activity is available for CE credit through June 2,2026.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

The following contributors have no relevant financial relationships with commercial interests to disclose:

Faculty

Darren W. Grabe, PharmD, BS

Pharmacy Times Continuing Education^™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Kylie Ferrentino; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green have no relevant financial relationships with commercial interests to disclose.
At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms